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1. Introductions 
Bone and soft tissue disease is kind of detrimental disease and the precise diagnosis and 
timely therapy is also the clinical doctors’ object of a prolonged endeavour. This chapter will 
introduce the diagnostic and therapeutic methods of bone and soft tissue diseases with 
nuclear medicine techniques.  
The singular advantages of skeletal scintigraphy are high sensitivity in detecting early 
disease and its ability to survey the entire skeleton quickly and reasonable expense. Most 
broadly, the uptake of skeletal seeking radiotracers depicts osteoblastic activity and regional 
blood flow to bone. Any medical condition that changes either of these factors in a positive 
or negative way can result in an abnormal skeletal scintigram. 
Radionuclide distribution has played an important role in understanding normal bone 
metabolism, in addition to the metabolic effects of pathologic involvement. Radionuclide 
imaging of the skeleton is being used with increasing frequency in the evaluation of 
abnormalities involving bones and joints. Several studies have demonstrated that different 
information can be obtained by radionuclide bone imaging compared with radiography and 
blood chemistry analysis. Innovations in equipment design and other advances, such as 
single-photon emission computed tomography (SPECT), positron emission tomography 
(PET), positron emission tomography/computed tomography (PET/CT), positron emission 
tomography/magnetic resonance imaging (PET/MR) and hybrid SPECT/CT have been 
incorporated into the investigation of various musculoskeletal diseases. 
The first part of this chapter introduces the mechanism of skeletal radionuclide imaging, 
which also reviews part knowledge of skeletal anatomy and physiology. The remainder of 
the chapter discusses radionuclide imaging of the bones and joints, with an emphasis on the 
applications of the imaging procedures, and the radionuclide therapy of some bone tumors. 
2. Mechanism and technique of skeletal radionuclide imaging 
Bone scintigraphy is one of the most common investigations performed in nuclear medicine 
and routinely used in the evaluation of patients with cancer for suspected bone metastases 
and in various benign musculoskeletal conditions. The uptake of radiotracers in bone is 
associated with local osteoblastic activity and regional blood flow. More 
radiopharmaceutical is delivered to hyperemic areas. Either increased blood flow or 
increased osteogenesis for many types of lesions results in higher tracer uptake than in 
unaffected or normal parts of the skeleton. 
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The accumulation of radionuclide in bone is related to both vascularity and rate of bone turn 
over. Increased blood supply to an area of bone result in increased activity in a blood-pool 
image (obtained immediately after radiopharmaceutical administration). 
The localization of various bone imaging agents is related to exchange with ions in the bone. 
The process of exchange of an ion native to bone for a labelled, bone-seeking ion is termed 
heter-ionic exchange. Calcium phosphate is the main inorganic constituent of bone; 
however, calcium is also found in the form of carbonate and fluoride. Calcium is located in 
microcystals of hydroxyapatite. Analog elements of calcium, such as strontium-85 (85Sr), are 
believed to exchange with the calcium. Flurorine-18 (18F) exchanges with hydroxyl ion in the 
hydroxyapatite. The accumulation of labelled phosphate compounds is probably related to 
the exchange of the phosphorus groups onto the calcium of hydroxyapatite. Although these 
mechanisms are not completely understood, the principle of bone imaging is fairly basic. 
Calcium analogs or phosphate compounds have a low concentration in blood and tissues, 
and this will supply a good bone-to-soft tissue background ratio. 
Radiopharmaceuticals used for bone imaging sometimes can localize in soft tissue areas, 
demonstrating not only calcification but also infarction, inflammation, trauma, and tumor. 
The portion of any radiopharmaceutical that does not accumulate in bone and tissue or stays 
in the circulation is eliminated from the body by various routes, depending on the 
radiopharmaceutical. 85Sr can be concentrated in the gastrointestinal tract for several days. 
18F-fluoride (18F-NaF) and phosphate scans labelled with technetium-99m (99mTc) 
demonstrate activity in the kidneys and bladder, since these agents are excreted through the 
urinary tract. 
2.1 Radiopharmaceuticals 
Because of different radiopharmaceutical defining the imaging type, it is necessary to 
introduce some tracers widely used in clinical departments. Radiopharmaceuticals are 
classified into three goups; single photon emitting agents, positron emitting agents and 
therapeutic radiopharmaceuticals according to the radiation types.  
2.1.1 Single photon emitting agents 
SPECT, which is short for single photon emission computer tomography, is the most widely 
used equipment in departments of nuclear medicine. There are lots of different kinds of 
single photon emitting radionuclides, however not all of them are suitable for skeleton 
imaging. The most widely used radionuclide is technetium-99m (99mTc). 
Technetium-99m is a metastable nuclear isomer of technetium-99, symbolized as 99mTc. 
Technetium- 99m emits gamma rays which can be detected by SPECT. It is well suited to the 
role because it emits readily detectable 140 keV (excitation energy) gamma rays, and its half-
life for gamma emission is about 6 hr. The short half life of the isotope (in terms of human-
activity and metabolism) allows for scanning procedures. The following table (table 1) 
summarizes its nuclear physics characteristics. 
The agents are composed of radiation emitter and chemical or biologic molecules. The Tc-
99m-labelled skeletal radiopharmaceuticals are distributed rapidly throughout the 
extracellular fluid space. For example, 99mTc-methylene diphosphonate (99mTc-MDP) is the 
most famous tracer of skeletal imaging, 99mTc (V)-2, 3-dimercaptosuccinic acid (99mTc (V)-
DSMA), and 99mTc-sestamibi (99mTc-MIBI) are also used in skeletal and soft tissue tumors 
imaging. 
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Nuclide 
symbol 
Z(p) N(n) isotopic mass (u)
half-life 
Decay 
mode(s) 
Daughter 
isotope(s) excitation energy 
99mTc 
43 56 98.9062547(21) 
6.0058 hr 
IT (99.99%) 99Tc 
140.5 keV β- (.0037%) 99Ru 
Table 1. The nuclear physics characteristics of radionuclide 99mTc 
Upon intravenous injection, the uptake of 99mTc-MDP appears to be related to bone 
metabolic activity and to skeletal blood flow. 99mTc-MDP exhibits a specific affinity for areas 
of altered osteogenesis. The adsorption is believed to occur primarily to the mineral phase of 
bone, with little biding to the organic phase. The uptake is significantly higher in 
amorphous calcium phosphate than in mature crystalline hydroxyapatite, which helps 
explain the avidity of the tracer for areas of increased osteogenic activity. Localized areas of 
decreased skeletal accumulation of 99mTc-MDP may be seen in areas of reduced or absent 
regional blood flow (i.e. bone infarction) and in areas where the skeleton has been destroyed 
to the point that no bone matrix elements are present for uptake to occur. 
99mTc (V)-DSMA and 99mTc-MIBI are usually used in seeking tumors in soft tissues. Also 
there are reports on the 99mTc (V)-DSMA scintigraphy as a monitor in the response of bone 
disease to vitamin D3 therapy in renal osteodystrophy and 99mTc (V)-DSMA whole body 
scan in detection of metastases in thyroid medullary cancer.  
Gallium-67 (67Ga) is also a single photon emitting radionuclide; it is an iron analogue which 
avidly binds to iron-binding proteins. It competes for iron sites in transferring and is 
absorbed by lysosomes and endoplasmic reticulum of white blood cells. It has been used in 
the evaluation of unknown original fever, chronic inflammations, detection and localization 
of osteomyelitis and/or disk space infection, etc. The excitation energy of 67Ga is 93.3 keV 
(36%) and has a life time of 3.26 days. 67Ga scintigraphy has been used to determine the 
treatment response in soft tissue tumors, such as osteosarcoma. 
Thalium-201 (201Tl) is another single photon emitting radionuclide, it has been used in many 
different SPECT imaging protocols such as myocardial perfusion imaging, skeleton imaging, 
tumor positive imaging, parathyroid imaging combined with pertechnetate, etc. 201Tl decays 
by electron capture and gamma emitter with subsequent gamma emission of 68.9 to 80.3 
keV (94%) and has a life time of 3.04 days. 
Although the role of 201Tl scintigraphy for staging the disease of bone tumor and 
differentiation of benign from malignant lesions is limited, it has provided important 
information on the management of patients with bone tumors. 201Tl scintigraphy reflects the 
disease activity after treatment and it should be used to determine the treatment response 
and for early diagnosis of recurrence in bone soft tissue tumors. 
2.1.2 Positron emitting agents 
PET, which is short for positron emission computed tomography, is the most advanced 
equipment in the field of nuclear medicine even in the area of image science. Lots of kinds of 
positron emitting radionuclide have been used in practice, such as 18F, 11C (carbon-11), 15O 
(oxygen-15), 13N (nitrogen-13), etc. The most widely used radionuclide is fluorine-18 (18F) 
and carbon-11 (11C). The 18F radiolabelled and 11C labelled skeletal radiopharmaceuticals are 
used in PET imaging, which reflect the bone metabolism. The following table (table 2) 
summarizes their nuclear physics characteristics. 
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Nuclide symbol 
Z(p) N(n) isotopic mass (u)
half-life 
Decay 
mode(s) 
Daughter 
isotope(s) excitation energy 
Fluorine-18 
18F 
9 9 18.0009380(6) 
109.7min 
Positron 
18O 
0.6335 MeV β- 
Carbon-11 
11C 
6 5 11.011433(10) 
20.33 min β+ 11B 
0.96 MeV 
Table 2. The nuclear physics characteristics of positron radionuclide 18F, 11C 
18F-2-fluoro-2-deoxy-d-glucose (18F-FDG), 18F sodium fluoride (18F-NaF) and 11C-choline PET 
imaging is also called bone metabolic imaging. Here we will mention 18F-FDG and 18F-NaF 
imaging. 18F-FDG (2-fluoro-2-deoxy-d-glucose) is a glucose analogue with a fluorine atom 
replacing a hydroxyl group in the C-2 position of d-glucose. 18F exchanges with the 
hydroxyl (OH) ion in the hydroxyapatite. Although the mechanisms are not completely 
understood, the principal of bone imaging is fairly basic. Radiopharmaceuticals used in 
bone imaging can localize in soft tissues, demonstrating not only calcification but also 
inflammation, trauma, and tumor. 
2.1.3 Therapeutic radiopharmaceuticals 
In the area of therapeutic nuclear medicine, there are lots of applications of different kinds 
of radiopharmaceuticals. For example, sodium of 32P-phosphate is an FDA-approved 
radiopharmaceutical indicated for treatment of polycythemia vera, chronic myelocytic 
leukemia, chronic lymphocytic leukemia, and for palliation of metastatic bone pain. 
Chromic 32P-phosphate is suspension of 32P used for intracavity installation for treatment of 
peritoneal or pleural effusions caused by metastatic disease. Phosphorus-32 decays by beta- 
emission with a half life of 14.3 days. The major toxicity noted is significant marrow 
suppression in approximately one third of patients receiving this radiopharmaceutical.  
Iodine-131 (131I) is the important therapeutic radiopharmaceutical, as a capsule or a solution 
for oral administration, which decays by beta- emission with subsequent gamma emission 
of 364 keV (82%) and has a life time of 8 days. Iodine-125 (125I) delivers a higher radiation 
dose to the patient due to the half life of 60 days and 125I seeds have been used in the therapy 
of solid tumors. 
In skeleton nuclear medicine, some radionuclides are chosen as an effective way for treating 
the bone pain caused by the bone metastases. 89Sr-chloride (Metastron) has been approved 
by the FDA for relief of bone pain in cases of painful skeletal metastases. The compound 
behaves biologically like calcium and localizes in hydroxyapatite crystal by ion exchange. 
Strontium uptake occurs preferentially at sites of active osteogenesis. This allows primary 
bone tumors and areas of metastatic involvement to accumulate significantly higher 
concentration of strontium than surrounding normal bone. 89Sr decays by beta- emission 
with a half life of 50.6 days.  
Another two radiotherapeutic agents, 186Re-HEDP and 153Sm-EDTMP are also used in the 
area. 186Re decays by beta- and gamma emission with a half life of 90.6 hr and 153Sm decays 
by beta- emission and has a half life of 46.3 hr. Both of these beta-emitting radionuclides are 
complex with bone-seeking ligands, which localize by chemisorption. The duration of 
response is 1-12 months. The main toxicity of these radiotherapeutics is mild transient bone 
marrow suppression. 
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2.1.4 Precautions 
In pediatric cases the physiology and metabolism is different from adults’ and the uptake of 
radiopharmaceuticals vary greatly, for example the bone uptake in children is up to 80% 
compared with that of adults at up to 40%. The pediatric dose of radiopharmaceuticals is 
calculated based on the standard weight method (the pediatric dose=(patient weight in 
kg×standard adult dose)÷70kg) or body surface area methods. With 99mTc labelled 
radiopharmaceuticals, we suggest a 24 to 36 hr breast feeding delay, and 67Ga based 
products for a 72 hr delay. 
In pregnant women, the nuclear medicine examinations are forbidden. 
2.2 Technique of skeletal radionuclide imaging 
After the radiopharmaceuticals prepared, an emission computed tomography is needed. 
Tomography is the process of producing a section or slice in a picture of an object. The 
emission computed tomography (ECT) can produce a picture of the distribution of 
radiopharmaceuticals administered to the patient. At present the widespread used ECT are 
SPECT and PET. 
2.2.1 Technique of skeleton SPECT imaging 
By far the most popular SPECT consists of a rotating Anger camera, which equipped with a 
large field of view detector, mounted on a 360-degree rotation gantry. Multipledetector 
SPECT has increased the diagnostic sensitivity and lessened the acquisition time. In skeletal 
imaging protocols we often chose a low energy and high resolution collimator. 
2.2.2 Technique of skeleton PET imaging 
PET is one of the exciting tomographic techniques, and provides functional information of 
blood flow and metabolism. As a positron meets a free electron in the tissue, annihilation 
occurs and the two 511keV annihilation photons are detected by coupled opposing detectors 
in coincidence. PET is more sensitivity than SPECT, and differs from SPECT by “electronic 
collimation”. 
2.3 Appearance of normal skeleton scintigram 
According to the different imaging objects, the nuclear physician chose the proper protocols. 
Generally speaking, the imaging type are divided into whole body scan, local static bone 
scan, local bone tomography, dynamic bone scan (i.e. three phase imaging: blood flow 
phase, blood-pool phase, and delay scan). The whole body bone scan is the most widely 
used scintigraphy, which reflects the whole skeleton situation.  
The appearance of the normal skeletal scintigram should be clear, symmetric and uniform 
and the uptake of joints, junctions, and scapulas increased. In some older patients the image 
may have a globally poor quality. The normal image can change dramatically among 
infancy, childhood, adolescence and mature adulthood. In adults, growth center activity 
normally becomes equal to activity in adjacent bone, on the contrary more radioactivities in 
growth center than adjacent bone in childhood. Tracer uptake is greatest in the axial 
skeleton (spine and pelvis), and relatively less intense uptake in the extremities and skull. 
The kidneys are routinely visualized in normal subjects and should have less intensity than 
the adjacent lumbar spine because the urinary system is the excretion pathway of the 
radiopharmaceuticals. If the kidneys show equal or greater intensity, a renal abnormality or 
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concomitant drug therapy should be suspected. Here shows a normal skeleton scintigram 
(Figure 1). 
 
 
Fig. 1. Normal skeletal scintigram shows the symmetric and uniform activity absorption in 
anterior and posterior image. 
A number of normal variants must be recognized for correct interpretation. Here we list 
some possible conditions as below.  遖Bilaterally increased radionuclide concentration may be normal.  遘The anterior aspect of the mandible may appear as a “hot spot” on lateral views of the 
skull.  遞The laryngotracheal cartilages are usually seen in adults probably related to some degree 
of calcification.  遨The thyroid gland can be visualized because of avid accumulation of unbound 
pertechnetate.  遯Some mild diffuse asymmetry in paired joints is commonly seen in adults especially in 
shoulders and correlates with handedness.  遶Some asymmetry is frequently seen in the sacroiliac joints, and this should be interpreted 
with caution in patients with scoliosis. 
3. Applications of skeletal radionuclide imaging 
 It is definite that the skeletal radionuclide imaging can present the information of blood 
flow and osteogenesis of regional area once. There are various abnormalities in skeletal 
radionuclide imaging, whatever the defects or increased uptake of radionuclide; they can 
manifest some clue of the lesions. We conclude some abnormal results as below, and 
describe the details as follow based on the clinical applications. 
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abnormality can happen in almost every scintigram. Focal increased activity can be 
associated with more blood flow (caused by hyperaemia, such as trauma, inflammation, etc) 
and active of osteogenesis (such as bone metastases of prostate cancer). 遘”Super scan” is another scintigraphic pattern, with good bone-to-soft tissue background 
ratio, bone uptake showing brightly, absent or faint visualization of kidney and bladder, an 
increased uptake in the axial versus appendicular skeleton (appendicular skeleton, distal 
extremities, facial bones, subtle asymmetries of the rib, skull vault, and proximal long bones, 
and no soft-tissue uptake apparent at normal intensities). In some patients with breast 
cancer or prostate cancer the entire axial skeleton becomes diffusely and rather uniformly 
involved with metastatic disease (Figure 2).  
 
 
Fig. 2. A patient diagnosed as prostate cancer, the whole body bone scan with 99mTc-MDP 
showed “super scan”: absent visualization of kidney, increased uptake in the axial versus 
appendicular skeleton and no soft-tissue uptake apparent at normal intensities. 遞Cold areas, which means diminished activity or none distribution of activity, is indicative 
of osteonecrosis, osteoporosis, osteomalacia, multiple myeloma, radiation or steroid 
therapy, end-stage cancer patients with diminished metabolism, renal cell carcinoma, 
thyroid cancer, anaplastic tumors, neuroblastoma. 遨”Donut” sign is the typical scintigram of osteonecrosis of the femoral head. The cold area 
within the femoral head is highly specific and is the earliest scintigraphic evidence of 
avascular necrosis. Over a period of weeks to months, increased uptake represents 
revascularization and repair surrounds, and eventually replaces the region of photopenia. 
The central region of photopenia with surrounding zone of increased uptake is termed as 
“donut” sign (Figure 3). 
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Fig. 3. The image showed “donut” sign in bilateral femoral head (worse in left side than 
right side), which is the diagnostic evidence of femoral head necrosis resulting from long-
time use of dexamethasone. 遯No uptake in focal areas: patients receive radiation therapy, bone infarct, avascular 
necrosis, metal prosthesis, bone infiltrated by tumor, poor venous return, edema in 
extremity may seen cold spot in focal area. 遶Three phase bone imaging: it is one of the types of imaging protocols, and can help the 
qualitative diagnosis of some skeletal diseases, such as increased uptake in flow, blood pool, 
and delays in osteomyelitis cases; increased uptake in flow and blood-pool with mild or no 
uptake in delays in cellutitis; increased activity in and around joints in flow, blood pool, and 
delays in arthritis; increased vascular flow, blood pool, and delays focally in primary 
malignant tumor (Figure 4); increased blood pool and delays, focally intense in benign 
primary tumor.  
 
 
Fig. 4. Three phase bone imaging showed increased activity in left distal femur in blood flow 
phase (A), blood pool phase (C), and delayed phase (D). Malignant bone tumor: blood 
supply obviously increased in blood flow phase, vascular extension can be seen. Irregular 
tracer accumulated in soft tissue, in blood pool phase. Hot spot accumulation can be found 
on bone in delayed phase. In this case the patient was diagnosed as left femur osteogenic 
sarcoma by pathological proven finally. 
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3.1 Metastatic diseases 
The most common clinical application of skeletal imaging is in evaluating patients with 
extraskeletal primary malignancies for the presence of metastatic disease and staging 
metastatic disease. In many patients the presence of extent of skeletal metastasis directly 
influences treatment decisions and prognosis. Bone imaging plays an important role in 
treatment of bone pain and pathological fracture which are common management problems 
in patients with skeletal metastatic disease.  
Anterior and posterior images of the whole body scan are generally obtained. Metastases to 
bone are common in several primary malignancies, including lung, breast, and prostate 
carcinomas (Figure 5-6). Metastases to the spine are difficult to detect radiographically, since 
loss of approximately 50% of the mineral content of the bone must occur before lytic lesions 
are detected. The usual scintigraphic pattern of skeletal metastatic disease is multiple focal 
lesions throughout the skeleton, with the greatest involvement generally in the axial 
skeleton. The area of abnormal radiopharmaceutical deposition represents the edge of the 
metastatic deposit where osteoblastic repair is attempted.  
As metastatic lesions grow in the marrow space, the surrounding bone remodels through 
osteoclastic (resorptive) and osteoblastic (depositional) activity. The relative degrees of bone 
resorption and deposition elicited are highly variable among the different types of tumors 
and sometimes even different locations for the same tumor. The relationship between the 
two remodelling processes determines whether a metastatic deposit will appear as 
predominantly lytic or sclerotic or will exhibit a mixed pattern radiographically.  
 
 
Fig. 5. The image showed multiple hot spot in skull, vertebrae, ribs, pelvis, femur, etc. 
Combined with the history of prostate cancer and night bone pain, it was concluded as bone 
metastases of prostate cancer. 
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Fig. 6. The image showed multiple focal lesions in bone of patient with breast cancer.  
False negative scans have been related to several factors. If the skeleton is diffusely involved 
with metastatic disease, the focal nature of the lesions might not be apparent. Metastatic 
lesions may have no associated osteoblastic activity and thus may not be detected by bone 
scan or may be detected as a photon-deficient area.  
3.2 Primary malignant bone tumors 
Bone scanning is also used for the evaluation of primary bone neoplasm. Usually the patient 
has already had radiographs of the primary tumor, but the bone scan offers additional 
information of that area. The extent of the abnormality on the bone scan is generally not 
much different from the radiographically apparent lesion. The value of bone scanning in 
patients with primary bone malignancy lies in the detection of the disease elsewhere.  
Uptake of bone-seeking radiopharmaceuticals in primary bone tumors is avid and 
frequently striking. PET imaging with FDG is being explored for primary bone tumors. FDG 
uptake correlates with tumor metabolism. Scans can be helpful in localizing sites for biopsy 
and in assessing response to preoperative radiation and chemotherapy. 
99mTc-MIBI have been used for sarcoma imaging to determine whether tumors are low or 
high grade and to assess response to therapy. As with FDG, high-grade tumors show higher 
uptake. Successful radiation therapy or chemotherapy is associated with decreasing uptake. 
Studies of primary tumor have led to at least one important observation about skeletal tracer 
uptake. Many tumors elicit marked hyperemia. The increased blood flow is not restricted to 
the tumor itself but affects the entire watershed distribution of regional flow, most 
characteristically involving an entire extremity (Figure 7).  
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Fig. 7. Anterior and posterior whole body scintigram of a patient with osteosarcoma in the 
left distal femur. The degree of tracer accumulation in the lesion is striking. Note also the 
“watershed” phenomenon with increased tracer accumulation in all of the bones of the left 
lower extremity above and below the lesion. The increased blood flow induced by the 
osteosarcoma results in increased tracer delivery to the entire limb.  
Another primary malignant disease commonly involving bone is multiple myeloma (MM). 
MM is really a disease of the red marrow space, and the most frequently involved skeletal 
structures are the vertebrae, pelvis, ribs, and skull (Figure 8). On skeletal scintigram the only 
finding in MM may be osteopenia. Unless an associated fracture or a focal lesion such as a 
plasmacytoma is present, skeletal scintigrams are often normal. MRI is an excellent modality 
for evaluating the marrow space for areas of involvement.  
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Fig. 8. Multiple myeloma, showed multiple focal accumulation of radioactivity in bone. 
3.3 Benign bone tumors 
 Skeletal imaging is highly sensitive for detecting osteoid osteomas (Figure 9), which can be 
difficult to find by standard radiography, especially in the spine.  
 
 
Fig. 9. Three phase bone scan (bottom row) of a 13 years old boy with history of pain and 
swelling in the right shin. The swelling was localized to the mid shaft of right tibia. Plain x-ray 
revealed a large area of sclerosis in the mid shaft of right tibia. Bone scan showed normal 
blood flow phase, high soft tissue uptake in the blood pool phase and a double density hot 
lesion in delayed image over the mid-shaft of right tibia. Surgical excision of the tumor 
resulted in total relief of symptoms. Histology confirmed the diagnosis of osteoid osteomas. 
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3.4 Trauma and athletic injuries 
Skeletal trauma is common and presents both an opportunity and a problem in skeletal 
scintigraphy. As we known, the first choice for suspected bone fracture is radiography, 
which shows the fracture line and type clearly. But SPECT bone imaging has its own 
advantages in some aspects. SPECT is a useful adjunct in the course of process such as stress 
fracture. Normal bone is constantly remodelling, bone resorption and deposition are 
balanced. When the skeleton is placed under stress the rate of remodelling increases, and 
that will result in change of activity in bone scintigraphy, 
The time a fracture takes to return to normal scintigraphically depends primarily on its 
location and the degree of damage to the skeleton.  
 
 
Fig. 10. Occult fracture of the left foot 4th toe, which can not be detected by radiography. 
3.5 Osteomyelitis 
In addition to being used in the evaluation of malignant disease involving the skeleton, 
radionuclide bone imaging is helpful in the assessment of several other non-malignant 
processes, such as patients with suspected osteomyelitis and diskitis. Acute hematogenous 
osteomyelitis typically begins by seeding of the infectious organism in the marrow space.  
A three-phase bone scan is performed by acquiring a rapid blood flow sequence of images 
over the interested area during agent injection. Early images (blood flow phase) are 
important in evaluating inflammatory processes. Flow images are performed 40 to 60sec and 
2 to 4 sec for each frame. Blood pool images are then immediately obtained for totally 300 to 
500 kcounts without moving the patient, and delayed images are taken as necessary. Both 
osteomyelitis and cellutitis can cause early increased radioactivity accumulation due to an 
increased vascular response to the affected area. The third phase is routine scanning at 2 to 3 
hr after injection. Sometimes there will be a forth phase that can be added 24hr delay. 
Osteomyelitis demonstrates focally increased activity in the involved bone on both the 
blood-pool and routine images (Figure 11). Since the use of bone imaging for detecting 
osteomyelitis, it has been found that several patients do not subsequently develop the 
typical radiographic changes because the early treatment prevents the development of 
radiographic abnormalities.  
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Fig. 11. Plantar view flow image show increased perfusion to the right proximal tibia. Blood-
pool image also demonstrate abnormal accumulation in the same area. Delayed image have 
persistent radiopharmaceutical collection consistent with osteomyelitis. Focal hyerperfusion, 
focal hyperemia, and focally increased bony activity in the proximal right tibial metaphysic 
are the classic findings of osteomyelitis.  
3.6 Metabolic bone diseases 
A number of metabolic conditions can result in marked abnormalities on bone imaging. 
Although these do not represent important clinical indications for bone imaging, they may 
be encountered incidentally in other applications, most importantly during metabolic 
skeletal survey. Hyperthyroidism, primary hyperparathyroidism, renal osteodystrophy, 
osteomalacia, and hypervitaminosis D all can result in generalized increased tracer uptake 
throughout the skeleton that has some features in common with the “supers can” seen in 
metabolic disease(Figure 12). These features are described before, such as increased  
 
 
Fig. 12. Supers can in metabolic disease from the patient with hyperparathyroidism 
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skeleton-to-soft tissue ratio and faint or absent visualization of the kidneys. Increased skull 
activity, involvement of the long bones of the extremities, and increased periarticular uptake 
are features that distinguish scan in these conditions from the supers can of metabolic 
disease. 
3.7 Bone marrow disorders 
Non-invasive imaging techniques have been used in the past for visualization the functional 
activity of the bone marrow compartment. Imaging with radiolabelled compounds may 
allow different bone marrow disorders to be distinguished. These imaging techniques, 
almost all of which use radiolabelled tracers, such as 99mTc-nanocolloid, 99mTc-sulphur 
colloid (99mTc-SC), 111In-chloride, and radiolabelled white blood cells (99mTc-WBC), have 
been used in nuclear medicine for several decades. The results support that the 
radiolabelled agents can be alternatives to bone marrow scan. 
4. Radionuclide therapy of skeletal tumors 
Metastatic bone cancer is a common complication of malignant tumor. It is reported that 
20%-75% of cancer patients has developed bone metastases according to necropsy results. 
Malignant bone pain is still a challenging clinical problem. Pain due to bone metastases will 
greatly decrease the patient’s quality-of-life because of patient’s gradual deterioration, local 
body dysfunction, and mental and physical collapse. Recently, there are several reports on 
therapy of painful bone metastases by radiotherapy or anticancer drugs showing 
therapeutic efficacy. The studies, however, were generally heterogeneous trials involving 
stage of diagnosis, radiopharmaceuticals dosage, combination with other therapeutic 
modalities and methods of pain assessment. In addition, there are few reports on the study 
of comparison of radionuclide therapy with chemotherapy for evaluating the therapeutic 
effectiveness of the patients with painful bone metastases. 
4.1 Radionuclide internal-radiation therapy 
Radionuclide internal-radiation therapy of severe bone pain due to multiple skeletal 
metastases has recently achieved successful stage in nuclear medicine, which has been much 
considered and widespread used. In this chapter we described the principle of treatment of 
painful disseminated skeletal metastases, therapeutic approaches, evaluation of effective 
treatment according to our clinical experience in routine clinical treatment and its future 
applications.  
89Sr-chloride (Metastron) has been approved by the FDA for relief of bone pain in cases of 
painful skeletal metastases. The compound behaves biologically like calcium and localizes in 
hydroxyapatite crystal by ion exchange. Strontium uptake occurs preferentially at sites of 
active osteogenesis. This allows primary bone tumors and areas of metastatic involvement 
to accumulate significantly higher concentrations of strontium than surrounding normal 
bone. 89Sr decays by beta- emission with a half life of 50.6 days. The conventional dose of 
89Sr-chloride is 148 MBq (4mCi), and can be reinjection after three months if necessary. 
Before administration, a blood regulation test should be checked. 
Another two radiotherapeutic agents, 186Re-HEDP and 153Sm-EDTMP are also used in the 
area. 186Re decays by beta- and gamma emission with a half life of 90.6 hr and 153Sm decays 
by beta- emission and has a half life of 46.3 hr. Both of these beta-emitting radionuclides are 
complex with bone-seeking ligands, which localize by chemisorption. The duration of 
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response is 1-12 months. The main toxicity of these radiotherapeutics is mild transient bone 
marrow suppression. 
4.2 Radionuclide seed implantation 
Radionuclide seed such as 125I、103Pd、198Au implantation has been used in lots of clinical 
departments. Mostly 125I seeds (Figure 13) have been chosen as the proper one. Iodine-125 
delivers a higher radiation dose to the patient due to the half life of 60 days and 125I seeds 
planted have been used in the therapy of solid tumors. 
 
 
 
 
Fig. 13. 125I seed is used in the therapy of solid tumor by implantation. 
5. Recent advances of skeletal radionuclide imaging and therapy 
It’s well-known that the skeletal radionuclide imaging and therapy will have a 
prospective development in novel radiopharmaceuticals of skeletal imaging (18F-NaF) 
(Figure 14) and therapy (heavy ion Carbon-11 and boron neutron capture therapy 
(BNCT)) and advanced nuclear medicine equipments such as SPECT/CT, PET/CT and 
PET/MR. In routine clinical practice, a variety of new radiopharmaceuticals have been 
introduced in recent years. There are three commercial radiopharmaceuticals of 
Samarium-153-ethylenediaminetetramethylene phosphonic acid (153Sm-EDTMP), 
Rehnium-188-(Sn)-hydroxyethylene diphosphonate (188Re-HEDP) and Strontium-89 
chloride (89SrCl2). 89SrCl2 is still the most widely used agent due to a longer physical half 
life (T½ = 50.5 days) and a pure beta-emitter playing an important role in radionuclide 
internal radiation therapy. 188Re-HEDP (T½ = 16.9 hr) obtained from 188W-188Re generator 
is cheap and convenient in clinical practice routine, with scintigraphic imaging of gamma 
rays in order to perform individual dosimetric studies, but 188W-188Re generator must be 
imported from other countries. 153Sm-EDTMP developed by our country is one of the 
radiopharmaceutical therapeutic agents and has relatively ideal physical, chemical and 
biological properties similar to 188Re except of slightly longer have-life (T½ = 40.4 hr). The 
0.103-Mev gamma ray is suitable for imaging in vivo distribution. The benefit of the 
favourable clinical experience with 153Sm-EDTMP has been reported in several 
multicenter trials.  
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                                a                                          b                                   c 
Fig. 14 Normal image of 18F- Fluoride PETȐa: 3D projection imaging  b: coronal slice 
iamging: c: sagittal slice imagingȑ 
6. Conclusion 
It is important to resolve the problems on skeletal and soft tissue tumors for clinicians to 
seek for new diagnostic and therapeutic radiopharmaceuticals. Although rapid 
developments of medical science and great progress have been made recently, there are still 
some limitations. The clinical applications of radionuclide tracing technique in diagnosis 
and treatment of skeletal and soft tissue tumor is attached importance to clinical physicians 
with widely using the technique in clinical routine practice and continuing development of 
nuclear medicine.  
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